PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

✍ Scribed by Loibl, S.; von Minckwitz, G.; Schneeweiss, A.; Paepke, S.; Lehmann, A.; Rezai, M.; Zahm, D. M.; Sinn, P.; Khandan, F.; Eidtmann, H.; Dohnal, K.; Heinrichs, C.; Huober, J.; Pfitzner, B.; Fasching, P. A.; Andre, F.; Lindner, J. L.; Sotiriou, C.; Dykgers, A.; Guo, S.; Gade, S.; Nekljudova, V.; Loi, S.; Untch, M.; Denkert, C.

• Book ID: 126629673
• Publisher: American Society of Clinical Oncology
• Year: 2014
• Tongue: English
• Weight: 274 KB
• Volume: 32
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2014.55.7876